Takeaways FGF21 and GDF15 analogs offer distinct mechanisms beyond GLP-1 for treating obesity and metabolic disease. Late-stage trials show promising effects on liver fat, appetite control, and thermogenesis with fewer GI side effects.…
Takeaways Brown fat activation raises calorie burn without suppressing appetite or affecting mood. Pharmacological BAT activation shows clinical promise with fewer side effects than older weight loss drugs. Combination strategies using BAT activators…
Takeaways Wearable nanobiosensors offer real-time hormone tracking through sweat or interstitial fluid. Closed-loop adaptive systems adjust HRT dosing based on live feedback instead of static lab tests. These technologies enhance precision and safety…
Takeaways Rapamycin may delay menopause by preserving ovarian reserve through targeted mTOR pathway inhibition. Reproductive aging impacts whole-body health, with genetics linking menopause timing to systemic longevity. Clinical trials like NCT05836025 mark a…
Takeaways MC4R agonists target the brain’s appetite center to support lasting weight maintenance after initial loss. Combining GLP‑1 and MC4R therapies enhances satiety control while minimizing metabolic rebound. Fountain of Youth SWFL leads…
Takeaways Bioengineered ovary scaffolds may one day restore hormone function more naturally than conventional HRT. These implants aim to mimic feedback loops and hormone cycles rather than deliver static doses. Clinical use remains…
Takeaways Bimagrumab plus GLP-1 therapy may preserve muscle while promoting near-total fat loss. Protecting lean mass improves long-term strength, metabolism, and quality of life. Functional outcomes, not just body composition, will shape future…
Takeaways RJVA-002 uses gene therapy to deliver GLP-1 and GIP directly from pancreatic beta cells in a nutrient-responsive way. Preclinical studies in obese mice show up to 30% body weight loss and improved…
Takeaways Once-monthly MariTide led to up to 17.5% weight loss in 52 weeks, with minimal regain after stopping treatment. The drug combines GLP-1 and glucagon receptor activity, offering fat burn and appetite suppression…
Takeaways Emerging GPCR-targeted therapies could offer oral, appetite-modifying weight-loss options with fewer GI side effects. GSBR-1290 shows real human efficacy (~5–7% weight loss) and convenience, while BRP highlights non-incretin, central-acting alternatives in preclinical…